System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Caroline Dutriaux is an expert in Oncology at Centre Hospitalier Universitaire de Bordeaux (France). As of September 2026, ScienceLeadR ranks Caroline Dutriaux in the top 1% of experts worldwide for Melanoma and Skin Neoplasms. Caroline Dutriaux has authored 345 publications, the most recent in 2026, and is an investigator in 37 clinical trials, 9 of them ongoing. SLR score: 1,358 (community average: 125). How the SLR is computed.

LeadR Profile

Caroline Dutriaux Centre Hospitalier Universitaire de Bordeaux France
1 358 ScienceLeadR Reputation 1358

Unlock

Register Login
Network Map

Oncology

Subspecialties: Biochemistry - Dermatology - Neurology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2014 - 2026
Source: PubMed

Centre Hospitalier Universitaire de Bordeaux

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 345

Citations

Citations: 22 538 1st author: 7 Last author: 11 Unique author: 0

Main journals

Ann Dermatol Venereol 74
J Clin Oncol 52
Ann Oncol 29
Eur J Cancer 24
Annales de Dermatologie et de Vénéréologie - FMC 18

Best Journals

J Clin Oncol 24
Ann Oncol 15
Lancet Oncol 10

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study.
PMID 42791653 — cells, merkel cells, somatostatin, neoplasms, therapeutics, dermatology, carcinoma, merkel cell		Cancer Med20260
primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.
PMID 42501621 — safety, melanoma, neoplasms, therapeutics, mutation		Eur J Cancer20260
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.
PMID 42025759 — cells, vaccines, progression-free survival, melanoma, neoplasms, drug-related side effects and adverse reactions, cancer vaccines		Ann Oncol Top journal20260
Main histopathological difficulties in diagnosing atypical melanocytic proliferations using MPATH-Dx V2: impact on patient management based on 6006 files referred for second opinions.
PMID 41605782 — melanoma, pathologists, pathology, classification, diagnosis		Pathology20250
Brief Communication: Severe Immuno-Induced Rhinosinusitis With Deafness After Ipilimumab and Nivolumab Combination for Melanoma, and Review of the Literature.
PMID 41430338 — ototoxicity, melanoma, communication, neoplasms, immune checkpoint inhibitors, nivolumab, therapeutics, hearing loss, ipilimumab, steroids, deafness, sinusitis, infliximab, rhinosinusitis		J Immunother20251

Clinical Studies 37

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5

By phase:

Phase 3 20
Phase 2 9
N/A 3
Phase 1 2
Phase 2/Phase 3 2
Phase 1/Phase 2 1

By status:

Completed 15
Active not recruiting 11
Recruiting 9
Terminated 1
Unknown 1

By type:

Interventional 35
Observational 2

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 4
multicentricup10 29

Main Topics

Ongoing Clinical Trials

9 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma
2023-503652-27-00 — melanoma, rna, messenger		Phase 3Active not recruiting2023
NEOREM NEO 1 NEOREM Neo adjuvant Immunotherapy Master Trial for Localized Cancers NEO 1 Neo adjuvant immunotherapy in patients with localized melanoma
2025-522127-95-00 — quality of life, disease-free survival, melanoma, neoplasms, immunotherapy, therapeutics		Phase 2Recruiting2026
A Study of Subcutaneous Nivolumab Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY 127)
2022-500967-11-00 — pharmaceutical preparations, melanoma, nivolumab		Phase 3Recruiting2023
Neo adjuvant Immunotherapy in Patients With Localized Melanoma
NCT07230613 — injections, melanoma, neoplasms, solutions, immunotherapy, neoadjuvant therapy, nivolumab, therapeutics, ipilimumab		Phase 2Recruiting2026
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First Line Therapy in Patients With Advanced Melanoma
NCT06697301 — toll-like receptors, safety, melanoma, neoplasms, neoplasm metastasis, therapeutics, toll-like receptor 7		Phase 2/Phase 3Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS